NCT02018419撤回1 期
In-Situ Cancer Vaccine: Phase I/IIb, Open-Label Study to Assess Safety of AllostimTM in Combination With Cryoablation in Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
适应症
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- To determine the safety of increased frequency of dosing
研究概览
简要总结
This phase I/II study is designed to compare different treatment schedules of a personalized anti-cancer vaccine protocol which combines the cryoablation of a selected metastatic lesion with intra-tumor immunotherapy. The cryoablation causes the tumor to release tumor-specific antigens into the surrounding environment. The injection of bioengineered allogeneic immune cells, AlloStim(TM), into the lesion is designed to modulate the immune response and educate the immune system to kill other tumor cells.
详细描述
The study will assess three different dosing schedules. A standard 3 plus 3 study design will be used. The starting dose for each dosing schedule will be escalated in subsequent groups of patients. The study will evaluate safety of increased frequency of AlloStim (TM) dosing and anti-tumor effect of the new proposed dose and frequency schedule.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women w/ histologically/cytologically confirmed breast carcinoma
- •Documented progressive metastatic disease not amenable to curative surgery/radiotherapy
- •Age ≥18 and ≤70 years
- •Prior treatments that included capecitabine and both an anthracycline and a taxane drug and resistant to taxane therapy
- •ER+ patients: minimum cumulative dose of anthracycline (≥ 180 mg/m² of doxorubicin or ≥ 300 mg/m² of epirubicin) or resistance to anthracycline, capecitabine and anti-hormonal therapy
- •Resistance is defined as tumor progression while receiving treatment or progression within 4 months of the last dose in the metastatic setting, or recurrence within 12 months in the neoadjuvant/adjuvant setting
- •Post-menopausal ER+ and/or PR+ must have received at least 2 lines of prior anti-estrogen therapy, which includes an aromatase inhibitor
- •Her2+ patients: at least 1 Her2+ targeted regimen containing trastuzumab alone or with pertuzumab/lapatinib. Trastuzumab/pertuzumab must have been discontinued at least 4 weeks before treatment
- •Prior radiation therapy completed >4 weeks before treatment
- •Measurable disease according to revised RECIST v.1.1 guidelines with at least 1 lesion deemed to be safely accessible for serial biopsy
- •Adequate hematological function
- •Absolute granulocyte count ≥ 1,500/mm3
- •Platelet count ≥ 100,000/mm3
- •PT/INR ≤ 1.5
- •INR correctable to ≤ 1.5 or a PT/PTT correctable to normal limits. Patients receiving anti-coagulation treatment with agent such as warfarin/heparin may participate. For patients on warfarin, INR should be monitored weekly prior to any intervention to assure INR is stable. Heparin/warfarin must be withheld before biopsy
- •Hemoglobin ≥ 9 g/dL (may be corrected by transfusion)
- •Adequate organ function
- •Creatinine ≤ 1.5 mg/dL
- •Total bilirubin ≤ 1.5 times ULN
- •Alkaline phosphatase≤2.5 times ULN (≤5 times normal if liver involvement)
- •Aspartate aminotransferase (AST/SGOT) ≤ 5.0 times ULN
- •Alanine aminotransferase (ALT/SGPT) ≤ 5.0 times ULN
- •EKG without clinically relevant abnormalities
- •Pre-menopausal with child bearing potential subjects must use adequate contraception
- •Informed consent in the native language of the subject
排除标准
- •Peritoneal carcinomatosis
- •Moderate-large ascites accumulation requiring/likely to require paracentesis
- •Clinical/radiological evidence of brain metastasis/leptomeningeal involvement
- •Pulmonary lymphangitis/symptomatic pleural effusion (grade ≥ 2) that results in pulmonary dysfunction requiring active treatment
- •History of 2nd primary malignancy, except: bilateral breast carcinoma, in situ carcinoma of the cervix, adequately treated non-melanomatous carcinoma of the skin, and other malignancy treated at least 5 years with no evidence of recurrence
- •>3 prior chemotherapy regimens for metastatic disease
- •History of severe hypersensitivity to monoclonal antibody drugs/any contraindication to study drugs
- •Pregnant or breast feeding
- •Any serious, concurrent uncontrolled medical disorder
- •Prior hepatectomy, liver chemoembolization, liver cryoablation/ radiofrequency ablated
- •Symptomatic pulmonary disease
- •Bevacizumab (Avastin®) within 3 weeks of accrual
- •Prior allogeneic bone marrow/stem cell or solid organ transplant
- •Chronic use (> 2 weeks) of greater than physiologic doses of corticosteroid agent (dose equivalent to > 10 mg/day of prednisone) within 30 days of the first day of study treatment. Topical and inhaled corticosteroids are permitted
- •Concomitant active autoimmune disease
- •Prior experimental therapy/cancer vaccine treatment
- •Current immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 1 month of study entry
- •History of blood transfusion reactions
- •Known allergy to bovine products
- •Know allergy to murine products
- •Progressive viral/bacterial infection. All infections must be resolved and the patient must remain afebrile for 7days without antibiotics prior to enrollment
- •Cardiac disease of symptomatic nature or cardiac ejection fraction < 45%
- •History of HIV positivity or AIDS
- •Psychiatric/addictive disorders or other condition that, in the opinion of the investigator, would preclude study participation
- •Concurrent medication known to interfere with platelet function or coagulation (e.g., aspirin, ibuprofen, clopidogrel, or warfarin) unless can be discontinued for an appropriate time period based on the drug half-life and known activity (e.g., aspirin for 7 days) prior to cryoablation procedure
- •Use of low molecular weight heparin preparations unless can be discontinued 8 hours prior to cryoablation
结局指标
主要结局
To determine the safety of increased frequency of dosing
时间窗: Window is defined as the time required receiving two doses of AlloStim IV push plus 28 days follow-up
Three patients are enrolled at each frequency schedule in the absence of dose limiting toxicity (DLT). A DLT is defined as any allergic or autoimmune toxicity or other study drug related toxicity Grade 3 or higher during the DLT assessment window.
次要结局
- Health-Related Quality of Life(From enrollment to 90 days after last dose administration.)
- Evaluate the anti-tumor effect of Allostim combined with cryoablation at the new proposed dose and frequency schedule.(90 days after last dose administration)
研究者
研究点 (2)
Loading locations...
相似试验
撤回
2 期
AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal CancerMetastatic Colorectal CancerNCT01741038Mirror Biologics, Inc.
已完成
2 期
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal CancerColorectal Cancer MetastaticNCT02380443Mirror Biologics, Inc.13
已完成
1 期
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor CryoablationMetastatic CancerNCT00861107Mirror Biologics, Inc.50
已完成
1 期
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV CancerSolid Tumors Stage II, Stage III and Stage IVBreast CancerProstate CancerColorectal CancerOvarian CancerNon-small Cell Lung CancerSarcomaMelanomaNCT01065441Michael Har-Noy9
撤回
2 期
Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & NeckSquamous Cell Carcinoma Head and NeckNCT02624999Mirror Biologics, Inc.